Science and Technology Science and Technology
Tue, February 14, 2012
Mon, February 13, 2012

CardioComm Solutions Receives a One Million Dollar Cash Infusion Through An Exercise of Warrants


Published on 2012-02-13 11:11:52 - Market Wire
  Print publication without navigation


February 13, 2012 14:03 ET

CardioComm Solutions Receives a One Million Dollar Cash Infusion Through An Exercise of Warrants

TORONTO, ONTARIO--(Marketwire - Feb. 13, 2012) - CardioComm Solutions, Inc., (TSX VENTURE:EKG) ("CardioComm" or the "Company") announced today that it completed a transaction involving a 10,000,000 common share purchase through the exercising of warrants by MD Primer Inc. ("MD Primer"). The warrants were provided to MD Primer under financing initiatives brokered over the past two years and have an exercise price of $0.10 per share. Gross proceeds from this transaction will go towards general working capital for CardioComm Solutions.

"MD Primer and its owner, Dr. Anatoly Langer, have long been supporters of CardioComm Solutions and it is an appropriate and timely move for these warrants to be exercised," said Etienne Grima, CardioComm Solutions' CEO. "The infusion of $1,000,000 in addition to the funds being raised from the Company's ongoing private placement will provide important financial resources to facilitate the continued roll out of our 2012 market development plans with the HeartCheck™ brand (PEN and the ECG Monitor), the C4 coordinating service and our Global ECG Management System (GEMS) 4.0 software platform. The transaction marks a milestone in our planned path to the globalization of our services and solutions."

About CardioComm Solutions, Inc.
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.